Drug intelligence / Profile preview

SiB-2191

Development stage: Preclinical
Lead developer: Signadori Bio
Modality: Immune Effector Cells → Other Cell Types → Cell Therapies

Overview

SiB-2191 is an *in vivo* monocyte immunotherapy being developed by Signadori Bio for the treatment of solid tumors. As part of the company's p21-engineered monocyte therapy platform, SiB-2191 is designed to reprogram or modulate monocyte function to stimulate anti-tumor immunity. Unlike other candidates in the Signadori pipeline (such as SiB-2101, SiB-2111, and SiB-2121) which target specific undisclosed secondary molecules, SiB-2191 is characterized as target-independent beyond its focus on p21 (CDKN1A). The therapy aims to leverage the natural recruitment of monocytes to the tumor microenvironment to deliver therapeutic effects. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on SiB-2191.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SiB-2191.

Explore the full profile